Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
The primary objectives are:
Phase 1b:
- To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of oprozomib given orally, once daily, on 2 different schedules.
- To evaluate safety and tolerability
Phase 2:
- To estimate the overall response rate (ORR).
- To evaluate safety and tolerability
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienorte
-
-
-
Lille CEDEX, Frankreich
- CHRU, Hopital Huriez - Department of Hematology
-
NANTES Cedex, Frankreich
- CHU Hôtel Dieu - Service d'Hématologie Clinique
-
Vandoeuvre Les Nancy, Frankreich
- CHU de NANCY - Hopital de BRABOlS
-
-
-
-
California
-
Los Angeles, California, Vereinigte Staaten
- USC/Norris Comprehensive Cancer Center
-
-
Florida
-
Tampa, Florida, Vereinigte Staaten
- H. Lee Moffitt Cancer Center & Research Institute
-
-
Kansas
-
Westwood, Kansas, Vereinigte Staaten
- University of Kansas Cancer Center and Medical Pavilion
-
-
Maryland
-
Bethesda, Maryland, Vereinigte Staaten
- Center for Cancer and Blood Disorders
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten
- Massachusetts General Hospital
-
Boston, Massachusetts, Vereinigte Staaten
- Dana-Farber Cancer Institute
-
-
Michigan
-
Detroit, Michigan, Vereinigte Staaten
- Karmanos Cancer Institute
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten
- Division of Hematology/ Oncology, UNC at Chapel Hill
-
-
Ohio
-
Canton, Ohio, Vereinigte Staaten
- Gabrail Cancer Center Research
-
-
Wisconsin
-
Milwaukee, Wisconsin, Vereinigte Staaten
- Froedtert Hospital and the Medical College of Wisconsin
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key Inclusion Criteria:
Diagnosis of multiple myeloma with measureable disease as indicated by 1 or more of the following:
- a. Serum M-protein ≥ 500 mg/dL
- b. Urine M-protein ≥ 200 mg/24 hours
- c. Only for subjects without measurable serum and urine M-protein, serum free light chain: Involved free light chain (FLC) level ≥ 10 mg/dL, provided serum FLC ratio is abnormal
- Patients requiring therapy who have relapsed and/or are refractory to their last therapy and have been treated with at least 1, but not more than 5, lines of multiple myeloma therapy. Prior therapy must have consisted of at least 1 regimen that included lenalidomide and/or bortezomib. Patients should be considered to be appropriate candidates for a clinical study by their treating physicians. Relapsed patients must have previously achieved ≥ minimal response (MR) on at least 1 line of therapy, as assessed by the treating physician. Refractory patients are allowed, but it is not required that patients be refractory to their last therapy. Primary refractory patients are allowed in the Phase 1b portion of the study only.
- Males and females ≥ 18 years of age
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2
- Adequate hepatic function, with bilirubin ≤ 1.5 times the upper limit of normal (ULN) in the absence of Gilbert's disease or hemolysis, aspartate aminotransferase (AST) ≤ 3 times ULN, and alanine aminotransferase (ALT) ≤ 3 times ULN
Absolute neutrophil count (ANC) ≥ 1000 cells/mcL, hemoglobin ≥ 7.0 g/dL, and platelet count ≥ 30,000 cells/mcL:
- a. Patients must not have received platelet transfusions for at least 1 week prior to Screening.
b. Screening ANC must be independent of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) support for at least 1 week and of pegylated G-CSF for
≥ 2 weeks prior to first dose.
- c. Patients may receive red blood cell (RBC) transfusions or receive supportive care with erythropoietin or darbepoetin in accordance with institutional guidelines.
- Calculated or measured creatinine clearance (CrCl) of ≥ 30 mL/minute calculated using the formula of Cockcroft and Gault ([140 - Age] * Mass (kg) / [72 * creatinine mg/mL]). Multiply result by 0.85 if female.
- Uric acid, if elevated, must be corrected to within laboratory normal range before dosing.
- Patients must sign a written informed consent form in accordance with federal, local, and institutional guidelines.
- Female patients of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to receiving the first dose of study drug and agree to use effective methods of contraception during the study and for 3 months following the last dose of study drug. Postmenopausal females (> 45 years old and without menses for > 1 year) and surgically sterilized females are exempt from these requirements. Male patients must use an effective barrier method of contraception during the study and for 3 months following the last dose if sexually active with a female of childbearing potential.
Prior carfilzomib is not required but is allowed if a patient had at least 2 cycles of carfilzomib alone or in combination with a dose of at least 20/27 mg/m^2, as long as the patient:
- a. Had at least a partial response to prior carfilzomib therapy
- b. Was not removed from carfilzomib therapy due to toxicity, unless approved by the medical monitor
- c. Was not removed from carfilzomib therapy for progressive disease nor experienced progressive disease within 6 months after any prior carfilzomib therapy.
Key Exclusion Criteria:
- Radiation therapy within 2 weeks prior to first dose; localized radiation therapy within 1 week prior to first dose
- Immunotherapy/standard myeloma therapy within 2 weeks prior to first dose (except for antibody therapy, where 6 weeks are required, and alkylator therapy, where 3 weeks are required); prior stem cell transplant (SCT) therapy (autologous SCT within the prior 8 weeks; allogeneic SCT within the prior 16 weeks). Patients with prior allogeneic SCT should not have evidence of moderate-to-severe graft-versus-host disease (GvHD).
- Plasmapheresis is not permitted at any time during the Screening period or while the subject is receiving study treatment. If a subject has started screening procedures requiring plasmapheresis, or is anticipated to require plasmapheresis during or after the Screening period, this patient will be considered ineligible and should not be enrolled.
- Glucocorticoid therapy within 14 days prior to enrollment that exceeds a cumulative dose of 160 mg of dexamethasone or equivalent
- Participation in an investigational therapeutic study within 3 weeks prior to first dose
- Prior oprozomib exposure
- Known hypersensitivity/toxicity or intolerance to dexamethasone
- Major surgery within 3 weeks prior to first dose
- Congestive heart failure ([CHF] New York Heart Association Class III to IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, or myocardial infarction within 6 months prior to first dose
- Uncontrolled hypertension or uncontrolled diabetes
- Active infection requiring systemic antibiotics, antivirals, or antifungals within 2 weeks prior to first dose
- Known or suspected human immunodeficiency virus (HIV) infection or patients who are HIV seropositive
- Active hepatitis A, B, or C infection
- History of previous clinically significant GI bleed in the last 6 months prior to first dose
- Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the first dose
- Other malignancy within the past 3 years, with the exception of adequately treated basal cell carcinoma of the skin, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the cervix, carcinoma in situ of the breast, prostate cancer of Gleason Score of 6 or less with stable prostate specific antigen levels, or cancer considered cured by surgical resection
- Plasma cell leukemia
- Female patients who are pregnant or nursing
- Inability to swallow medication, inability or unwillingness to comply with the drug administration requirements, or GI condition that could interfere with the oral absorption or tolerance of treatment
- Any contraindication to oral hydration (e.g., significant preexisting comorbidity or fluid restriction)
- Any clinically significant psychiatric or medical condition that in the opinion of the investigator could increase patient risk or interfere with protocol adherence or a patient's ability to give informed consent.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Cohort 180 mg 5/14 Schedule (Phase 1b)
Oprozomib 180 mg treatment once daily for 5 consecutive days bimonthly (days 1, 2, 3, 4, and 5 of a 14-day cycle) with 20 mg dexamethasone once daily on days 1, 2, 8, and 9 (referred to as the 5/14 schedule).
Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
|
Oprozomib tablets were supplied containing 60, 90, or 120 mg of oprozomib.
Oprozomib extended release tablets were supplied containing 150, 180, 210, 240, or 270 mg of oprozomib.
Both formulations were administered in a single dose on dosing days.
The tablet formulation required multiple tablets to reach each dose on dosing days.
Andere Namen:
Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally.
If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.
|
|
Experimental: Cohort 210 mg 5/14 Schedule (Phase 1b)
Oprozomib 210 mg treatment once daily for 5 consecutive days bimonthly (days 1, 2, 3, 4, and 5 of a 14-day cycle) with 20 mg dexamethasone once daily on days 1, 2, 8, and 9 (referred to as the 5/14 schedule). Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason. This was the first cohort to enroll participants into the 5/14 schedule. The Cohort Safety Review Committee (CSRC) reviewed safety data and made dose adjustments for oprozomib in 30 mg increments for all cohorts. |
Oprozomib tablets were supplied containing 60, 90, or 120 mg of oprozomib.
Oprozomib extended release tablets were supplied containing 150, 180, 210, 240, or 270 mg of oprozomib.
Both formulations were administered in a single dose on dosing days.
The tablet formulation required multiple tablets to reach each dose on dosing days.
Andere Namen:
Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally.
If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.
|
|
Experimental: Cohort 150/180 mg 5/14 Schedule (Phase 1b)
Oprozomib 150 mg once daily treatment for 5 consecutive days (days 1, 2, 3, 4, and 5 of a 14-day cycle) followed by a step-up in oprozomib once daily dose to 180 mg starting in cycle 2 and moving forward.
Dexamethasone 20 mg once daily was administered on days 1, 2, 8, and 9 of each 14-day cycle.
Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
|
Oprozomib tablets were supplied containing 60, 90, or 120 mg of oprozomib.
Oprozomib extended release tablets were supplied containing 150, 180, 210, 240, or 270 mg of oprozomib.
Both formulations were administered in a single dose on dosing days.
The tablet formulation required multiple tablets to reach each dose on dosing days.
Andere Namen:
Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally.
If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.
|
|
Experimental: Cohort 210 mg 2/7 Schedule (Phase 1b)
Oprozomib 210 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason. This was the first cohort to enroll participants into the 2/7 schedule. The Cohort Safety Review Committee (CSRC) reviewed safety data and made dose adjustments for oprozomib in 30 mg increments for all cohorts. |
Oprozomib tablets were supplied containing 60, 90, or 120 mg of oprozomib.
Oprozomib extended release tablets were supplied containing 150, 180, 210, 240, or 270 mg of oprozomib.
Both formulations were administered in a single dose on dosing days.
The tablet formulation required multiple tablets to reach each dose on dosing days.
Andere Namen:
Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally.
If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.
|
|
Experimental: Cohort 240 mg 2/7 Schedule (Phase 1b)
Oprozomib 240 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle.
Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
|
Oprozomib tablets were supplied containing 60, 90, or 120 mg of oprozomib.
Oprozomib extended release tablets were supplied containing 150, 180, 210, 240, or 270 mg of oprozomib.
Both formulations were administered in a single dose on dosing days.
The tablet formulation required multiple tablets to reach each dose on dosing days.
Andere Namen:
Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally.
If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.
|
|
Experimental: Cohort 270 mg 2/7 Schedule (Phase 1b)
Oprozomib 270 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle.
Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
|
Oprozomib tablets were supplied containing 60, 90, or 120 mg of oprozomib.
Oprozomib extended release tablets were supplied containing 150, 180, 210, 240, or 270 mg of oprozomib.
Both formulations were administered in a single dose on dosing days.
The tablet formulation required multiple tablets to reach each dose on dosing days.
Andere Namen:
Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally.
If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.
|
|
Experimental: Cohort 300 mg 2/7 Schedule (Phase 1b)
Oprozomib 300 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle.
Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
|
Oprozomib tablets were supplied containing 60, 90, or 120 mg of oprozomib.
Oprozomib extended release tablets were supplied containing 150, 180, 210, 240, or 270 mg of oprozomib.
Both formulations were administered in a single dose on dosing days.
The tablet formulation required multiple tablets to reach each dose on dosing days.
Andere Namen:
Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally.
If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.
|
|
Experimental: Cohort 330 mg 2/7 Schedule (Phase 1b)
Oprozomib 330 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle.
Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
|
Oprozomib tablets were supplied containing 60, 90, or 120 mg of oprozomib.
Oprozomib extended release tablets were supplied containing 150, 180, 210, 240, or 270 mg of oprozomib.
Both formulations were administered in a single dose on dosing days.
The tablet formulation required multiple tablets to reach each dose on dosing days.
Andere Namen:
Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally.
If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.
|
|
Experimental: Phase 2 300 mg 2/7 Schedule
The Cohort Safety Review Committee (CSRC) determined this dose as the recommended phase 2 dose (RP2D).
Oprozomib 300 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle.
Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
|
Oprozomib tablets were supplied containing 60, 90, or 120 mg of oprozomib.
Oprozomib extended release tablets were supplied containing 150, 180, 210, 240, or 270 mg of oprozomib.
Both formulations were administered in a single dose on dosing days.
The tablet formulation required multiple tablets to reach each dose on dosing days.
Andere Namen:
Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally.
If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Participants With Dose-Limiting Toxicities (DLT)
Zeitfenster: Day 1 to Day 14 (Cycle 1) for continous dosing and Day 15 to Day 28 (Cycle 2) for step-up dosing
|
Toxicities (graded per the Common Terminology Criteria for Adverse Events v 4.03) were considered DLTs if judged by the investigator to be related to oprozomib and occurred in the first 14 days of treatment, with treatment at the dose to be studied (i.e., Cycle 1 for continuous dosing or Cycle 2 for step-up dosing). A DLT was categorized as nonhematologic or hematologic. Examples include:
|
Day 1 to Day 14 (Cycle 1) for continous dosing and Day 15 to Day 28 (Cycle 2) for step-up dosing
|
|
Participants With Treatment-Emergent Adverse Events (TEAEs) During Phase 1b and 2
Zeitfenster: Day 1 up to Week 282
|
AE defined as any untoward medical occurrence in a clinical trial participant. Treatment-emergent adverse events were defined as adverse events that start on or after the first day of study treatment and within 30 days of the last day of study treatment. An adverse event that was present before the first administration of study treatment and subsequently worsens in severity during treatment was also considered to be treatment-emergent. Serious AE defined as AE that is fatal, life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or other significant medical hazard. Severity of AEs assessed according to Common Terminology Criteria for Adverse Events (CTCAE, v4.03) based on the general guideline: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening or disabling; Grade 5: Death related to AE. IP=investigational product |
Day 1 up to Week 282
|
|
Participants With Treatment-Related, Treatment-Emergent Adverse Events (TEAEs) During Phase 1b and 2
Zeitfenster: Day 1 up to Week 282
|
AE defined as any untoward medical occurrence in a clinical trial participant. TEAEs were defined as AEs that start on or after the first day of study treatment and within 30 days of the last day of study treatment. An AE that was present before the first administration of study treatment and subsequently worsens in severity during treatment was also considered a TEAE. Investigator assessed AEs for relatedness to study drug. Serious AE defined as AE that is fatal, life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or other significant medical hazard. Severity of AEs assessed according to Common Terminology Criteria for Adverse Events (CTCAE, v4.03) based on the general guideline: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening or disabling; Grade 5: Death related to AE. IP=investigational product |
Day 1 up to Week 282
|
|
Best Overall Response in Phase 2 as Assessed by Investigator
Zeitfenster: Screening: Day 14 to Day -1; During study: Day 1 up to 13.16 months
|
Disease response and progression were determined using the International Myeloma Working Group-Uniform Response Criteria (IMWG-URC), except for minimal response (MR) and near complete response (nCR) which was based on the European Group for Blood and Marrow Transplantation (EBMT) criteria.
Evaluations reported were assessed by the investigator for participants in Phase 2.
|
Screening: Day 14 to Day -1; During study: Day 1 up to 13.16 months
|
|
Percentage of Participants Who Achieved an Overall Response As Assessed by Investigator During Phase 2
Zeitfenster: Screening: Day 14 to Day -1; During study: Day 1 up to 13.16 months
|
The overall response rate (ORR) was defined as the percentage of participants with the best overall response of stringent complete response (sCR), complete response (CR), near complete response (nCR), very good partial response (VGPR), and partial response (PR) as defined by the International Myeloma Working Group-Uniform Response Criteria (IMWG-URC) and modified European Group for Blood and Marrow Transplantation (EBMT) criteria.
|
Screening: Day 14 to Day -1; During study: Day 1 up to 13.16 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Pharmacokinetic (PK) Parameter for Oprozomib, Tablet and ER Formulation: Time to Maximum Serum Concentration (Tmax) on Cycle 1, Day 1
Zeitfenster: Day 1
|
PK samples obtained on the following schedule: Phase 1b Continuous Dosing, Cycles 1 and 2: Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 8 hours post-dose plus pre-dose on Day 2 Phase 1b Step-up Dosing, Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 7 hours post-dose plus pre-dose on Day 2 Phase 2, Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 7 hours post-dose plus pre-dose on Day 2 |
Day 1
|
|
Pharmacokinetic (PK) Parameter for Oprozomib, Tablet and ER Formulation: Maximum Serum Concentration (Cmax) on Cycle 1, Day 1
Zeitfenster: Day 1
|
PK samples obtained on the following schedule: Phase 1b Continuous Dosing, Cycles 1 and 2: Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 8 hours post-dose plus pre-dose on Day 2 Phase 1b Step-up Dosing, Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 7 hours post-dose plus pre-dose on Day 2 Phase 2, Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 7 hours post-dose plus pre-dose on Day 2 |
Day 1
|
|
Pharmacokinetic (PK) Parameter for Oprozomib, Tablet and ER Formulation: Area Under the Curve at the Last Measurable Time Point (AUClast) on Cycle 1, Day 1
Zeitfenster: Day 1
|
The area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUClast) was estimated using the linear trapezoidal method. PK samples obtained on the following schedule: Phase 1b Continuous Dosing, Cycles 1 and 2: Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 8 hours post-dose plus pre-dose on Day 2 Phase 1b Step-up Dosing, Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 7 hours post-dose plus pre-dose on Day 2 Phase 2, Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 7 hours post-dose plus pre-dose on Day 2 |
Day 1
|
|
Pharmacokinetic (PK) Parameter for Oprozomib, Tablet and ER Formulation: Area Under the Curve From Time 0 to Time Infinity (AUCinf) on Cycle 1, Day 1
Zeitfenster: Day 1
|
The area under the plasma concentration-curve from time 0 to time infinity (AUCinf) was estimated using the linear trapezoidal method PK samples obtained on the following schedule: Phase 1b Continuous Dosing, Cycles 1 and 2: Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 8 hours post-dose plus pre-dose on Day 2 Phase 1b Step-up Dosing, Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 7 hours post-dose plus pre-dose on Day 2 Phase 2, Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 7 hours post-dose plus pre-dose on Day 2 |
Day 1
|
|
Pharmacokinetic (PK) Parameter for Oprozomib, Tablet and ER Formulation: Terminal Half-Life (t1/2,z) on Cycle 1, Day 1
Zeitfenster: Day 1
|
PK samples obtained on the following schedule: Phase 1b Continuous Dosing, Cycles 1 and 2: Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 8 hours post-dose plus pre-dose on Day 2 Phase 1b Step-up Dosing, Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 7 hours post-dose plus pre-dose on Day 2 Phase 2, Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 7 hours post-dose plus pre-dose on Day 2 |
Day 1
|
|
Pharmacokinetic (PK) Parameter for Oprozomib, Tablet and ER Formulation: Apparent Drug Clearance After Oral Administration (CL/F) on Cycle 1, Day 1
Zeitfenster: Day 1
|
The apparent drug clearance after oral administration (CL/F) was calculated as the dose divided by AUCinf. PK samples obtained on the following schedule: Phase 1b Continuous Dosing, Cycles 1 and 2: Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 8 hours post-dose plus pre-dose on Day 2 Phase 1b Step-up Dosing, Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 7 hours post-dose plus pre-dose on Day 2 Phase 2, Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 7 hours post-dose plus pre-dose on Day 2 |
Day 1
|
|
Pharmacokinetic (PK) Parameter for Oprozomib, Tablet and ER Formulation: Apparent Volume of Distribution After Oral Administration (Vz/F) on Cycle 1, Day 1
Zeitfenster: Day 1
|
The apparent volume of distribution after oral administration (Vz/F) calculated as the dose divided by AUCinf times ƒz, where ƒz was the first-order terminal rate constant estimated via linear regression of the terminal log-linear phase. PK samples obtained on the following schedule: Phase 1b Continuous Dosing, Cycles 1 and 2: Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 8 hours post-dose plus pre-dose on Day 2 Phase 1b Step-up Dosing, Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 7 hours post-dose plus pre-dose on Day 2 Phase 2, Day 1: pre-dose, post-dose at 15 and 30 minutes, 1, 2, 4, 6, and 7 hours post-dose plus pre-dose on Day 2 |
Day 1
|
|
Percentage of Participants Who Achieved a Clinical Benefit Response As Assessed by Investigator During Phase 2
Zeitfenster: Screening: Day 14 to Day -1; During study: Day 1 up to 13.16 months
|
The clinical benefit rate (CBR) was defined as Overall Response Rate (ORR) plus Minimal Response (MR) as defined by the European Group for Blood and Marrow Transplantation (EBMT) criteria.
|
Screening: Day 14 to Day -1; During study: Day 1 up to 13.16 months
|
|
Kaplan-Meier Estimates for Duration of Response (DOR) as Assessed by Investigator During Phase 2
Zeitfenster: Day 1 up to 13.16 months
|
Duration of response was defined as the time from first evidence of partial response (PR) or better (i.e.
best overall response) to confirmation of disease progression or death due to any cause.
Durations were calculated for responders only.
Medians and percentiles were estimated using the Kaplan-Meier method.
95% confidence intervals for medians and percentiles were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.
|
Day 1 up to 13.16 months
|
|
Kaplan-Meier Estimates for Progression-free Survival (PFS) as Assessed by Investigator During Phase 2
Zeitfenster: Day 1 up to 14.1 months
|
Progression-free survival (PFS) was defined as number of months between start of treatment and first evidence of documented disease progression or death (due to any cause), whichever occurs first. Disease progression was determined using IMWG-URC per investigator. The duration of PFS was right-censored for participants who met 1 of the following conditions:
|
Day 1 up to 14.1 months
|
|
Kaplan-Meier Estimate for Time to Progression (TTP) as Assessed by Investigator During Phase 2
Zeitfenster: Day 1 up to 14.1 months
|
Time to progression (TTP) was defined as the number of months between the start of treatment to the first documentation of disease progression. Disease progression was determined using IMWG-URC as assessed by the investigator. The same censoring rules, except for death, as in analysis of PFS were applied in the calculation of TTP. Participants who died prior to progressive disease were censored at the date of last evaluable response assessment. |
Day 1 up to 14.1 months
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Herz-Kreislauf-Erkrankungen
- Gefäßerkrankungen
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Neubildungen
- Lymphoproliferative Erkrankungen
- Immunproliferative Erkrankungen
- Hämatologische Erkrankungen
- Hämorrhagische Störungen
- Hämostasestörungen
- Paraproteinämien
- Bluteiweißstörungen
- Multiples Myelom
- Neubildungen, Plasmazelle
- Physiologische Wirkungen von Arzneimitteln
- Autonome Agenten
- Agenten des peripheren Nervensystems
- Entzündungshemmende Mittel
- Antineoplastische Mittel
- Antiemetika
- Magen-Darm-Mittel
- Glukokortikoide
- Hormone
- Hormone, Hormonersatzstoffe und Hormonantagonisten
- Antineoplastische Mittel, hormonell
- Dexamethason
Andere Studien-ID-Nummern
- 2012-001 (Andere Zuschuss-/Finanzierungsnummer: Meriter Hospital)
- 20130408 (Andere Kennung: Amgen)
- 2013-001169-18 (EudraCT-Nummer)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Multiples Myelom
-
University Hospital, CaenLaphalAbgeschlossen
Klinische Studien zur Oprozomib
-
AmgenBeendetMultiples Myelom | Waldenstrom-MakroglobulinämieVereinigte Staaten
-
AmgenZurückgezogenFortgeschrittenes hepatozelluläres KarzinomVereinigte Staaten
-
AmgenBeendetMultiples MyelomVereinigte Staaten
-
AmgenAbgeschlossenMultiples MyelomGriechenland, Italien, Niederlande
-
AmgenBeendetFortgeschrittene Malignome des nicht-zentralen Nervensystems (ZNS).Vereinigte Staaten
-
AmgenBeendetMultiples MyelomVereinigte Staaten